DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Enhancer of zeste homolog 2 (EZH2) tri-methylates histone 3 at position lysine 27 (H3K27me3). Overexpression and gain-of-function mutations in EZH2 are regarded as oncogenic drivers in lymphoma and other malignancies due to the silencing of tumor suppressors and differentiation genes. EZH2 inhibitio...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0220681 |
| _version_ | 1819123752082866176 |
|---|---|
| author | Chidimma Agatha Akpa Karsten Kleo Dido Lenze Elisabeth Oker Lora Dimitrova Michael Hummel |
| author_facet | Chidimma Agatha Akpa Karsten Kleo Dido Lenze Elisabeth Oker Lora Dimitrova Michael Hummel |
| author_sort | Chidimma Agatha Akpa |
| collection | DOAJ |
| description | Enhancer of zeste homolog 2 (EZH2) tri-methylates histone 3 at position lysine 27 (H3K27me3). Overexpression and gain-of-function mutations in EZH2 are regarded as oncogenic drivers in lymphoma and other malignancies due to the silencing of tumor suppressors and differentiation genes. EZH2 inhibition is sought to represent a good strategy for tumor therapy. In this study, we treated Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) cell lines with 3-deazaneplanocin-A (DZNep), an indirect EZH2 inhibitor which possesses anticancer properties both in-vitro and in-vivo. We aimed to address the impact of the lymphoma type, EZH2 mutation status, as well as MYC, BCL2 and BCL6 translocations on the sensitivity of the lymphoma cell lines to DZNep-mediated apoptosis. We show that DZNep inhibits proliferation and induces apoptosis of these cell lines independent of the type of lymphoma, the EZH2 mutation status and the MYC, BCL2 and BCL6 rearrangement status. Furthermore, DZNep induced a much stronger apoptosis in majority of these cell lines at a lower concentration, and within a shorter period when compared with EPZ-6438, a direct EZH2 inhibitor currently in phase II clinical trials. Apoptosis induction by DZNep was both concentration-dependent and time-dependent, and was associated with the inhibition of EZH2 and subsequent downregulation of H3K27me3 in DZNep-sensitive cell lines. Although EZH2, MYC, BCL2 and BCL6 are important prognostic biomarkers for lymphomas, our study shows that they poorly influence the sensitivity of lymphoma cell lines to DZNep-mediated apoptosis. |
| first_indexed | 2024-12-22T07:13:20Z |
| format | Article |
| id | doaj.art-caba97a9a72749c886982bacc5b06676 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T07:13:20Z |
| publishDate | 2019-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-caba97a9a72749c886982bacc5b066762022-12-21T18:34:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01148e022068110.1371/journal.pone.0220681DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.Chidimma Agatha AkpaKarsten KleoDido LenzeElisabeth OkerLora DimitrovaMichael HummelEnhancer of zeste homolog 2 (EZH2) tri-methylates histone 3 at position lysine 27 (H3K27me3). Overexpression and gain-of-function mutations in EZH2 are regarded as oncogenic drivers in lymphoma and other malignancies due to the silencing of tumor suppressors and differentiation genes. EZH2 inhibition is sought to represent a good strategy for tumor therapy. In this study, we treated Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) cell lines with 3-deazaneplanocin-A (DZNep), an indirect EZH2 inhibitor which possesses anticancer properties both in-vitro and in-vivo. We aimed to address the impact of the lymphoma type, EZH2 mutation status, as well as MYC, BCL2 and BCL6 translocations on the sensitivity of the lymphoma cell lines to DZNep-mediated apoptosis. We show that DZNep inhibits proliferation and induces apoptosis of these cell lines independent of the type of lymphoma, the EZH2 mutation status and the MYC, BCL2 and BCL6 rearrangement status. Furthermore, DZNep induced a much stronger apoptosis in majority of these cell lines at a lower concentration, and within a shorter period when compared with EPZ-6438, a direct EZH2 inhibitor currently in phase II clinical trials. Apoptosis induction by DZNep was both concentration-dependent and time-dependent, and was associated with the inhibition of EZH2 and subsequent downregulation of H3K27me3 in DZNep-sensitive cell lines. Although EZH2, MYC, BCL2 and BCL6 are important prognostic biomarkers for lymphomas, our study shows that they poorly influence the sensitivity of lymphoma cell lines to DZNep-mediated apoptosis.https://doi.org/10.1371/journal.pone.0220681 |
| spellingShingle | Chidimma Agatha Akpa Karsten Kleo Dido Lenze Elisabeth Oker Lora Dimitrova Michael Hummel DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations. PLoS ONE |
| title | DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations. |
| title_full | DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations. |
| title_fullStr | DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations. |
| title_full_unstemmed | DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations. |
| title_short | DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations. |
| title_sort | dznep mediated apoptosis in b cell lymphoma is independent of the lymphoma type ezh2 mutation status and myc bcl2 or bcl6 translocations |
| url | https://doi.org/10.1371/journal.pone.0220681 |
| work_keys_str_mv | AT chidimmaagathaakpa dznepmediatedapoptosisinbcelllymphomaisindependentofthelymphomatypeezh2mutationstatusandmycbcl2orbcl6translocations AT karstenkleo dznepmediatedapoptosisinbcelllymphomaisindependentofthelymphomatypeezh2mutationstatusandmycbcl2orbcl6translocations AT didolenze dznepmediatedapoptosisinbcelllymphomaisindependentofthelymphomatypeezh2mutationstatusandmycbcl2orbcl6translocations AT elisabethoker dznepmediatedapoptosisinbcelllymphomaisindependentofthelymphomatypeezh2mutationstatusandmycbcl2orbcl6translocations AT loradimitrova dznepmediatedapoptosisinbcelllymphomaisindependentofthelymphomatypeezh2mutationstatusandmycbcl2orbcl6translocations AT michaelhummel dznepmediatedapoptosisinbcelllymphomaisindependentofthelymphomatypeezh2mutationstatusandmycbcl2orbcl6translocations |